A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..

This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed the informed consent will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. A detailed explanation can be provided by the investigator conducting the study.

Study Overview

• Status: Terminated
• Conditions: Prostate Cancer
• Intervention / Treatment: Drug: Aplidin (plitidepsin)

Detailed Description

Prostate cancer is the most common non-cutaneous cancer diagnosed in men in the United States. The majority of deaths occur in men with androgen-independent prostate cancer [AIPC]. Although 80% of men with advanced cancer will initially respond to androgen ablation with disease regression or stabilization, their malignancies become resistant to such therapy.

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Michigan
    • Ann Arbor, Michigan, United States, 48109-0473
      • University of Michigan Comprehensive Cancer Center
  • Washington
    • Seattle, Washington, United States, 98109
      • Seattle Cancer Care Alliance

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Written informed consent before starting any study-specific procedure. If any patient is unable to give consent, it may be obtained from the patient's legal representative if in accordance with local laws and regulations.

2. Men with castrate metastatic adenocarcinoma of the prostate, with the following characteristics:

   • Confirmed pathological diagnosis.
   • Metastatic disease (radiologically documented).
   • All patients with chemical castration must have a serum testosterone level below 50 ng/ml. There is no need to document a serum testosterone in patients having a prior surgical castration2.
   • Baseline PSA > 5 ng/ml (according to the recommendations from the Prostate-Specific Antigen Working Group2).

   • Androgen-independent progressive disease, as defined by detectable, rising PSA in two consecutive measurements at least one week apart:

     • If PSA responded to a prior therapy, progression occurs when the PSA is 50% above the nadir level.
     • If PSA did not respond to a prior therapy, progression occurs when the PSA increases by 25% or more above pretreatment levels.
     • In both cases, the increase in absolute value PSA level must be at least 5 ng/ml, and must be confirmed by a second measurement a minimum of 1 week later.
   • Patients must have received prior docetaxel-based chemotherapy.
3. Recovery from any toxicity derived from previous treatments. The presence of alopecia and NCI-CTC grade < 2 sensitive peripheral neuropathy is allowed.
4. Age > 18 years.
5. Performance status (ECOG) < 2.
6. Life expectancy > 3 months.

7. Adequate renal, hepatic, and bone marrow function (assessed < 14 days before inclusion in the study):

   • Neutrophil count ³ 1.5 x 109/L.
   • Platelet count ³ 100 x 109/L. Hemoglobin > 9 g/dl.
   • Creatinine clearance ³ 40 ml/min (calculated from the Cockcroft and Gault formula), see Appendix 3.
   • Serum bilirubin * 1.5 mg/dl.
   • AST, ALT < 2.5 x ULN (< 5 x ULN in case of liver metastasis).
   • Albumin > 25 g/L.
8. Left ventricular ejection fraction within normal limits

Exclusion Criteria:

1. Prior therapy with Aplidin®.
2. Concomitant therapy with any anti-tumor agent, including glucocorticoids at a daily dose greater than 10 mg prednisone or equivalent, except when they were indicated for symptom control, provided that disease progression was documented while on steroids.
3. Small cell carcinoma of the prostate.
4. More than two previous lines of systemic therapy for patient's castrate metastatic disease, considering biological agents or chemotherapy as systemic therapy.
5. Patients with progressive measurable disease but without increased PSA value (according to the consensus recommendations) will not be considered eligible.

6. Wash-out periods less than:

   • 6 weeks after the last dose of a nitroso-urea or high dose chemotherapy
   • 4 weeks after the last dose of other chemotherapies or biological agents
   • 6 weeks after the end of treatment with extensive external beam radiation (more than 25% of bone marrow distribution) or radionuclide therapy.
   • 4 weeks after the end of treatment with palliative radiation involving less than 25% of bone marrow reserves.
   • 4 weeks for major prior surgery
   • 30 days after receiving any other investigational product
7. Men of reproductive potential who are not using effective contraceptive methods, considering complete abstinence from intercourse throughout the treatment with the study drug and for at least 6 months after completion or premature discontinuation from the study as an effective contraceptive method, to be sure that the patient's female partner does not become pregnant.

8. History of another neoplastic disease. The exceptions are:

   8.1 Non-melanoma skin cancer. 8.2 Any other cancer curatively treated with no evidence of disease for at least 10 years.

9. Known symptomatic cerebral or leptomeningeal involvement.

10. Other relevant diseases or adverse clinical conditions:

    • History or presence of unstable angina, myocardial infarction, valvular heart disease or congestive heart failure.
    • Previous mediastinal radiotherapy.
    • Uncontrolled arterial hypertension despite optimal medical therapy.
    • Previous treatment with doxorubicin at cumulative doses in excess of 400 mg/m².
    • Symptomatic arrhythmia or any arrhythmia requiring treatment.

    • Abnormal ECG as detailed below:

      • QT interval prolongation:
      • QTc> 480 msec.
      • Left ventricular hypertrophy :
      • Sokolow Index: (R V5 or V6) + S V1)> 3.5mv.
      • Left bundle-branch block:
      • Complete: QRS> 0.12 sec. No Q wave is seen in leads V5 and V6. A notched R wave is seen in left leads and a notched S wave in right side leads.
      • Right bundle-branch block:
      • Complete: QRS> 0.12 sec. Secondary R (R') wave in leads V1-V2. Slurred S wave in leads D1 ,avL, V5 and V6.
      • Second-degree atrioventricular (av) block:
      • Mobitz I AV block, or Wenckebach block: Progressive prolongation of the PR interval causing progressive R-R interval shortening until a P wave fails to conduct the ventricle. The RR interval containing the blocked P wave is shorter than the sum of the twPP interval.
      • Mobitz II AV block is characterized by sudden unexpected blocked P waves without variation or prolongation of the PR interval. It can be 2:1, 3:1, 4:1 etc.
      • Third-degree atrioventricular block:
      • P waves and QRS complexes without mutual relationship. P wave rate is greater than that of QRS complexes.
      • Ischemia, injury and infarction:
      • Subendocardial ischemia. - Symmetrical T waves of increased amplitude.
      • Subepicardial ischemia. - Inverted symmetrical T waves.
      • Subendocardial injury. - ST segment depression (horizontal or descending).
      • Subepicardial injury. - ST segment elevation with upper convexity.
      • Infarction or necrosis. - Q wave voltage greater than 25% of R wave voltage.
      • Duration of Q wave is 0.04 sec or more
    • History of significant neurological or psychiatric disorders.
    • Active infection; infection by HIV, HBV or HCV. HIV, HBV or HCV testing are not required unless infection is clinically suspected.
    • Myopathy or any clinical situation that causes significant and persistent elevation of CK (> 2.5 ULN in two different determinations performed with one week apart).
    • Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).
    • Limitation of the patient's ability to comply with the treatment or follow-up protocol.
    • Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or hyperthyroidism) (i.e. requiring relevant changes in medication within the last month, or hospital admission within the last 3 months).
11. Known hypersensitivity to Aplidin®, mannitol, cremophor EL, or ethanol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Aplidin (Plitidepsin)	Drug: Aplidin (plitidepsin); Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The Percentage of Patients With a ≥ 50% Prostate-specific Antigen (PSA) Decline Post-therapy	All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Tumor Response According to RECIST	Patients with an objective tumor response (complete response [CR] or partial response [PR]) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST), See Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16.	All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Progression Free Survival (PFS)	To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after 2 previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy. PFS defined as time from the first day of study treatment to the day of a negative outcome (progression according to RECIST (Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16) or death) or last contact. If any patient is lost to follow up before disease progression, the PFS will be censored at the date of the last tumor assessment. If there are no tumor assessments the patient will be censored at the first drug administration date.	All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Overall Survival (OS)	To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy. Survival is measured from the first day of study treatment to death or day of their last follow-up	All patients were followed up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment visit of the last patient, whichever occured first
Pain Improvement Rate	To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy. Expressed as a change in pain intensity according to the pain intensity score on the 100 mm VAS (Visual Analogue Scale) and/or change in analgesic (morphine-equivalent mg) requirements after a pain stabilization period of 2-7 days Visual Analogue Scale (VAS), expressed in the pain intensity score on the 100 mm VAS scale (0=least possible pain to 100=worst possible pain)	2-7 days for the pain stabilization required at baseline to ensure that baseline values are stable and reliable. The follow-up period was up to progressive disease, start of a new anti-cancer therapy, death or one year after the last treatment
PSA Slope Between Baseline PSA Value and Nadir After the Start of Treatment	To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy. It was calculated as (nadir value-baseline value)/(nadir date-baseline date). Modifications in the slope of PSA changes before and after the start of treatment with Aplidin will also be explored.	From baseline until progression or initiation of another anticancer therapy, death or one year after the last treatment visit of the last patient, whichever occurred first.

Collaborators and Investigators

• Sponsor: PharmaMar
• Investigators: Principal Investigator: Celestia Higano, M.D., Seattle Cancer Care Alliance; Principal Investigator: Maha Hussain, M.D., University of Michigan Rogel Cancer Center

Study record dates

Study Major Dates

• Study Start: February 1, 2005
• Primary Completion (Actual): March 1, 2008
• Study Completion (Actual): March 1, 2008

Study Registration Dates

• First Submitted: October 27, 2008
• First Submitted That Met QC Criteria: October 27, 2008
• First Posted (Estimate): October 28, 2008

Study Record Updates

• Last Update Posted (Actual): November 24, 2020
• Last Update Submitted That Met QC Criteria: November 16, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: Cancer; Prostate; Aplidin; Plitidepsin
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms
• Other Study ID Numbers: APL-B-011-02